|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SULF2 |
Gene summary for SULF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SULF2 | Gene ID | 55959 |
| Gene name | sulfatase 2 | |
| Gene Alias | HSULF-2 | |
| Cytomap | 20q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q8IWU5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55959 | SULF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.79e-10 | -5.02e-01 | 0.0155 |
| 55959 | SULF2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.22e-06 | -4.10e-01 | 0.096 |
| 55959 | SULF2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.83e-02 | -4.27e-01 | 0.0338 |
| 55959 | SULF2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.17e-04 | -3.52e-01 | 0.0674 |
| 55959 | SULF2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.81e-08 | -3.39e-01 | 0.294 |
| 55959 | SULF2 | F007 | Human | Colorectum | FAP | 3.62e-06 | -4.72e-01 | 0.1176 |
| 55959 | SULF2 | A002-C-010 | Human | Colorectum | FAP | 1.35e-19 | -4.65e-01 | 0.242 |
| 55959 | SULF2 | A001-C-207 | Human | Colorectum | FAP | 5.79e-14 | -5.44e-01 | 0.1278 |
| 55959 | SULF2 | A015-C-203 | Human | Colorectum | FAP | 2.96e-26 | -5.25e-01 | -0.1294 |
| 55959 | SULF2 | A015-C-204 | Human | Colorectum | FAP | 1.02e-08 | -4.27e-01 | -0.0228 |
| 55959 | SULF2 | A014-C-040 | Human | Colorectum | FAP | 7.68e-05 | -5.69e-01 | -0.1184 |
| 55959 | SULF2 | A002-C-201 | Human | Colorectum | FAP | 6.40e-15 | -4.68e-01 | 0.0324 |
| 55959 | SULF2 | A002-C-203 | Human | Colorectum | FAP | 9.02e-17 | -4.98e-01 | 0.2786 |
| 55959 | SULF2 | A001-C-119 | Human | Colorectum | FAP | 1.90e-06 | -4.34e-01 | -0.1557 |
| 55959 | SULF2 | A001-C-108 | Human | Colorectum | FAP | 4.46e-21 | -5.13e-01 | -0.0272 |
| 55959 | SULF2 | A002-C-021 | Human | Colorectum | FAP | 1.99e-02 | -3.05e-01 | 0.1171 |
| 55959 | SULF2 | A002-C-205 | Human | Colorectum | FAP | 1.46e-21 | -5.58e-01 | -0.1236 |
| 55959 | SULF2 | A001-C-104 | Human | Colorectum | FAP | 2.24e-10 | -4.45e-01 | 0.0184 |
| 55959 | SULF2 | A015-C-005 | Human | Colorectum | FAP | 2.01e-11 | -5.06e-01 | -0.0336 |
| 55959 | SULF2 | A015-C-006 | Human | Colorectum | FAP | 1.98e-09 | -3.21e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00600702 | Colorectum | MSS | canonical Wnt signaling pathway | 86/3467 | 303/18723 | 1.58e-05 | 3.56e-04 | 86 |
| GO:00608282 | Colorectum | MSS | regulation of canonical Wnt signaling pathway | 74/3467 | 253/18723 | 1.99e-05 | 4.26e-04 | 74 |
| GO:00226122 | Colorectum | MSS | gland morphogenesis | 41/3467 | 118/18723 | 2.02e-05 | 4.30e-04 | 41 |
| GO:00301771 | Colorectum | MSS | positive regulation of Wnt signaling pathway | 44/3467 | 140/18723 | 1.57e-04 | 2.28e-03 | 44 |
| GO:00974212 | Colorectum | MSS | liver regeneration | 16/3467 | 35/18723 | 2.07e-04 | 2.89e-03 | 16 |
| GO:00506731 | Colorectum | MSS | epithelial cell proliferation | 108/3467 | 437/18723 | 6.76e-04 | 7.30e-03 | 108 |
| GO:00311001 | Colorectum | MSS | animal organ regeneration | 25/3467 | 76/18723 | 1.91e-03 | 1.66e-02 | 25 |
| GO:00902631 | Colorectum | MSS | positive regulation of canonical Wnt signaling pathway | 32/3467 | 106/18723 | 2.41e-03 | 1.96e-02 | 32 |
| GO:00030121 | Colorectum | MSS | muscle system process | 105/3467 | 452/18723 | 6.39e-03 | 4.26e-02 | 105 |
| GO:0001655 | Colorectum | MSS | urogenital system development | 81/3467 | 338/18723 | 6.88e-03 | 4.43e-02 | 81 |
| GO:0050678 | Colorectum | MSS | regulation of epithelial cell proliferation | 90/3467 | 381/18723 | 6.92e-03 | 4.45e-02 | 90 |
| GO:0031099 | Colorectum | MSS | regeneration | 51/3467 | 198/18723 | 6.99e-03 | 4.49e-02 | 51 |
| GO:00487324 | Colorectum | FAP | gland development | 103/2622 | 436/18723 | 3.61e-08 | 3.12e-06 | 103 |
| GO:00160553 | Colorectum | FAP | Wnt signaling pathway | 104/2622 | 444/18723 | 4.92e-08 | 3.92e-06 | 104 |
| GO:01987383 | Colorectum | FAP | cell-cell signaling by wnt | 104/2622 | 446/18723 | 6.26e-08 | 4.54e-06 | 104 |
| GO:00301113 | Colorectum | FAP | regulation of Wnt signaling pathway | 81/2622 | 328/18723 | 1.44e-07 | 9.03e-06 | 81 |
| GO:00608283 | Colorectum | FAP | regulation of canonical Wnt signaling pathway | 62/2622 | 253/18723 | 5.26e-06 | 1.69e-04 | 62 |
| GO:00600703 | Colorectum | FAP | canonical Wnt signaling pathway | 71/2622 | 303/18723 | 6.23e-06 | 1.96e-04 | 71 |
| GO:00610084 | Colorectum | FAP | hepaticobiliary system development | 41/2622 | 150/18723 | 1.32e-05 | 3.55e-04 | 41 |
| GO:00018894 | Colorectum | FAP | liver development | 40/2622 | 147/18723 | 1.88e-05 | 4.70e-04 | 40 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SULF2 | SNV | Missense_Mutation | rs367871609 | c.518N>T | p.Thr173Met | p.T173M | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SULF2 | SNV | Missense_Mutation | c.1203G>C | p.Leu401Phe | p.L401F | Q8IWU5 | protein_coding | tolerated(0.21) | benign(0.035) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SULF2 | SNV | Missense_Mutation | rs149787530 | c.1492G>A | p.Gly498Arg | p.G498R | Q8IWU5 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SULF2 | SNV | Missense_Mutation | rs781507832 | c.1181N>A | p.Arg394Gln | p.R394Q | Q8IWU5 | protein_coding | tolerated(0.08) | benign(0.017) | TCGA-BH-A0HI-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| SULF2 | SNV | Missense_Mutation | c.955N>A | p.Gly319Ser | p.G319S | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD | |
| SULF2 | insertion | Frame_Shift_Ins | novel | c.454_455insTCCAGTTTGGGGTTATTACAAATAGCGCTGCTGA | p.Tyr152PhefsTer25 | p.Y152Ffs*25 | Q8IWU5 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SULF2 | insertion | Frame_Shift_Ins | novel | c.511_512insGCCGGGTGTGTTGGCACATGCCTGTGGACCCAGCTACTAGAGAG | p.Asn171SerfsTer24 | p.N171Sfs*24 | Q8IWU5 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SULF2 | SNV | Missense_Mutation | novel | c.502N>T | p.Arg168Cys | p.R168C | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SULF2 | SNV | Missense_Mutation | novel | c.1225N>T | p.Arg409Trp | p.R409W | Q8IWU5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SULF2 | SNV | Missense_Mutation | c.439N>A | p.Glu147Lys | p.E147K | Q8IWU5 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |